[{"orgOrder":0,"company":"Alvotech","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ DKSH"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Partnership","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Advanz Pharma"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : AVT05 is a biosimilar candidate for Simponi and Simponi Aria (golimumab). Golimumab is a monoclonal antibody that inhibits TNF alpha implicated in several chronic inflammatory diseases.

                          Product Name : AVT05

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          January 27, 2025

                          Lead Product(s) : Golimumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Teva Pharmaceutical Industries

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The net proceeds for this financing will be used to fund the clinical advancement of company's late-stage product AVT05 (golimumab), which is being evaluated for the treatment of rheumatoid arthritis.

                          Product Name : AVT05

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          November 07, 2024

                          Lead Product(s) : Golimumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : AVT16 (vedolizumab) is an integrin receptor antagonist indicated in adults for the treatment of moderately to severely active ulcerative colitis & crohn's disease.

                          Product Name : AVT16

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 25, 2024

                          Lead Product(s) : Vedolizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : AVT05 (golimumab) is a TNF blocker indicated for treating moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in adults.

                          Product Name : AVT05

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 24, 2024

                          Lead Product(s) : Golimumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : AVT05 is a biosimilar candidate for Simponi and Simponi Aria (golimumab). Golimumab is a monoclonal antibody that inhibits TNF alpha implicated in several chronic inflammatory diseases.

                          Product Name : AVT05

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 11, 2024

                          Lead Product(s) : Golimumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : AVT05 (golimumab) is a TNF alpha Inhibitor antibody drug therapy, administered intravenously, it is being investigated for rheumatoid arthritis management.

                          Product Name : AVT05

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 29, 2023

                          Lead Product(s) : Golimumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : AVT05 (golimumab) is a biosimilar candidate for Simponi® and Simponi Aria®. It is a monoclonal antibody that inhibitsTNF alpha, elevated TNF alpha levels have been implicated in several chronic inflammatory diseases such as rheumatoid arthritis, psoria...

                          Product Name : AVT05

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 01, 2023

                          Lead Product(s) : Golimumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Teva and Alvotech are working on pending approval in the U.S. for AVT02 (adalimumab), a biosimilar candidate for Humira and it also includes four other biosimilars, one of which is AVT04, a proposed biosimilar for Stelara (ustekinumab), with pending FDA ...

                          Product Name : Simlandi

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          July 24, 2023

                          Lead Product(s) : Adalimumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Teva Pharmaceutical Industries

                          Deal Size : $40.0 million

                          Deal Type : Partnership

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : AVT02 (adalimumab-aqvh) is a monoclonal antibody which inhibits tumor necrosis factor. It binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors.

                          Product Name : Simlandi

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 13, 2023

                          Lead Product(s) : Adalimumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : AVT05 is a biosimilar candidate for Simponi and Simponi Aria (golimumab). Golimumab is a monoclonal antibody that inhibits tumor necrosis factor alpha (TNF alpha), a cytokine protein in the body. It is being investigated for moderate to severe rheumatoid...

                          Product Name : AVT05

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 05, 2023

                          Lead Product(s) : Golimumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank